BioAge Labs, Inc. (BIOA) Wednesday announced a multi-year collaboration with Novartis to discover and validate multiple therapeutic drug therapies for age-related diseases and conditions.
Currently, BIOA is trading at $4.22, up 3.11 percent on a volume of 2,560,920.
As per the agreement, BioAge will receive upfront payments and research funding of up to $20 million, plus up to $530 million in future long-term milestones. The collaboration will be eligible for reciprocal success milestones and tiered royalties.
Collaboration is expected to leverage BioAge's differentiated human longevity data and platform and Novartis expertise in the biology of physical exercise to identify drug targets.
The collaboration will leverage BioAge's extensive proprietary human longevity datasets and Novartis expertise in exercise biology.
For comments and feedback: editorial@rttnews.com